Report Code : CVMI24071664 | Published Date : July 16, 2024

The Adalimumab drugs market is experiencing significant growth, fueled by the increasing adoption of biologics for treating autoimmune diseases, a rise in biosimilar approvals, and a growing prevalence of rheumatoid arthritis (RA), psoriasis, and Crohn’s disease. The market was valued at USD XX billion in 2019 and reached USD XX billion in 2023. It is projected to grow at a CAGR of XX% from 2024 to 2031, reaching USD XX billion by 2031.

Adalimumab Drugs Market Key Insights

Adalimumab, a TNF-alpha inhibitor, is widely used to treat rheumatoid arthritis, psoriasis, ulcerative colitis, and inflammatory bowel disease (IBD). The expansion of biosimilars, personalized biologic therapies, and subcutaneous self-injection drug delivery is reshaping the market.

Adalimumab Drugs Market Growth Drivers

  • Rising Cases of Autoimmune Diseases and Chronic Inflammatory Disorders – The increasing prevalence of rheumatoid arthritis, psoriasis, and Crohn’s disease is driving the demand for adalimumab demand.
  • Expansion of biosimilar approvals and market competition – Cost-effective adalimumab biosimilars are enhancing affordability for patients access.
  • Advancements in Subcutaneous and Auto-Injectable Drug Delivery – Innovations in user-friendly self-injector devices and prolonged formulations are improving treatment adherence.
  • Regulatory Approvals and Patent Expirations Fueling Biosimilar Growth – FDA and EMA approvals for adalimumab biosimilars are transforming the market competition.

 

Adalimumab Drugs Market Regional Trends

  • North America excels due to robust biological adoption and widespread use of biosimilars accessibility.
  • Europe is expanding through government-backed biosimilar programs and enhanced healthcare cost containment efforts.
  • Asia-Pacific is experiencing rapid growth due to the rising prevalence of autoimmune diseases and biosimilars investments.
  • Latin America and MEA are emerging markets that are benefiting from increased access to biosimilars and enhanced healthcare policies.

 

ClearView Market Insights Analysis:

The Adalimumab drug market is poised for continuous expansion, fueled by the adoption of biosimilars, the rising prevalence of autoimmune diseases, and innovations in biologic drug delivery. Companies that invest in cost-effective biosimilars, patient-centric self-injection devices, and AI-driven personalized biologic therapies will lead this evolving sector.





Reasons To Buy

Image



Scope

Image

Key Players

  • AbbVie Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Sandoz International GmbH (a Novartis division)

 

Global Adalimumab Drugs Market Report

  1. 1. Global Adalimumab Drugs Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Global Adalimumab Drugs Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
    2. Global Adalimumab Drugs Market Research Report - Preface
    1. 2.1 Global Adalimumab Drugs Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Indication
      2. 2.1.2 By Distribution Channel
      3. 2.1.3 By Region
    3. Global Adalimumab Drugs Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Indication, By Distribution Channel, By Country
    3. 3.3. Opportunities – By Indication, By Distribution Channel, By Country
    4. 3.4. Trends – By Indication, By Distribution Channel, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Global Adalimumab Drugs Market Research Report – DROTs Impact Analysis
    4. Global Adalimumab Drugs Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    1. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    2. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    3. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    4. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    5. Global Adalimumab Drugs Market, By Indication, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 Rheumatoid Arthritis
      1. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 5.2 Psoriasis
      1. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    3. 5.3 Crohn's Disease
      1. 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    4. 5.4 Ulcerative Colitis
      1. 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    5. 5.5 Ankylosing Spondylitis
      1. 5.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 5.6 Others
      1. 5.6.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 5.6.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 5.6.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 5.6.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Global Adalimumab Drugs Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Hospital Pharmacies
      1. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 6.2 Specialty Clinics
      1. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    7. Global Adalimumab Drugs Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 North America
      1. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    2. 7.2 Europe
      1. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    3. 7.3 Asia-Pacific
      1. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    4. 7.4 Latin America
      1. 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    5. 7.5 Middle East & Africa
      1. 7.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 7.6 Global Adalimumab Drugs Market - Opportunity Analysis Index, By Indication, By Distribution Channel, and Region, 2024 - 2031
    8. North America Global Adalimumab Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.1.1 Rheumatoid Arthritis
      2. 8.1.2 Psoriasis
      3. 8.1.3 Crohn's Disease
      4. 8.1.4 Ulcerative Colitis
      5. 8.1.5 Ankylosing Spondylitis
      6. 8.1.6 Others
      8.2 By Distribution Channel Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.2.1 Hospital Pharmacies
      2. 8.2.2 Specialty Clinics
      8.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.3.1 United States
      2. 8.3.2 Canada
      8.4 North America Global Adalimumab Drugs Market – Opportunity Analysis Index, By Indication, By Distribution Channel, and Country, 2024 - 2031
      8.5 Regional Trends Analysis
      8.6 North America Global Adalimumab Drugs Market Research Report - Company Profiles
      1. 8.6.1 Company 1 (United States)
      2. 8.6.2 Company 2 (Canada)
      3. 8.6.3 Company 3 (Canada)
    9. Europe Global Adalimumab Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 9.1 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 Rheumatoid Arthritis
      2. 9.1.2 Psoriasis
      3. 9.1.3 Crohn's Disease
      4. 9.1.4 Ulcerative Colitis
      5. 9.1.5 Ankylosing Spondylitis
      6. 9.1.6 Others
      9.2 By Distribution Channel Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Hospital Pharmacies
      2. 9.2.2 Specialty Clinics
      9.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Germany
      2. 9.3.2 United Kingdom
      3. 9.3.3 France
      4. 9.3.4 Spain
      5. 9.3.5 Italy
      6. 9.3.6 Russia
      7. 9.3.7 Netherlands
      8. 9.3.8 Poland
      9. 9.3.9 Rest of Europe
      9.4 Europe Global Adalimumab Drugs Market – Opportunity Analysis Index, By Indication, By Distribution Channel, and Country, 2024 - 2031
      9.5 Regional Trends Analysis
      9.6 Europe Global Adalimumab Drugs Market Research Report - Company Profiles
      1. 9.6.1 Company 1 (Germany)
      2. 9.6.2 Company 2 (United Kingdom)
      3. 9.6.3 Company 3 (United Kingdom)
    10. Asia-Pacific Global Adalimumab Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 10.1 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.1.1 Rheumatoid Arthritis
      2. 10.1.2 Psoriasis
      3. 10.1.3 Crohn's Disease
      4. 10.1.4 Ulcerative Colitis
      5. 10.1.5 Ankylosing Spondylitis
      6. 10.1.6 Others
      10.2 By Distribution Channel Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.2.1 Hospital Pharmacies
      2. 10.2.2 Specialty Clinics
      10.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.3.1 China
      2. 10.3.2 Japan
      3. 10.3.3 India
      4. 10.3.4 South Korea
      5. 10.3.5 Australia & NZ
      6. 10.3.6 ASEAN
      7. 10.3.7 Rest of Asia-Pacific
      10.4 Asia-Pacific Global Adalimumab Drugs Market – Opportunity Analysis Index, By Indication, By Distribution Channel, and Country, 2024 - 2031
      10.5 Regional Trends Analysis
      10.6 Asia-Pacific Global Adalimumab Drugs Market Research Report - Company Profiles
      1. 10.6.1 Company 1 (China)
      2. 10.6.2 Company 2 (Japan)
      3. 10.6.3 Company 3 (Japan)
    11. Latin America Global Adalimumab Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 11.1 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.1.1 Rheumatoid Arthritis
      2. 11.1.2 Psoriasis
      3. 11.1.3 Crohn's Disease
      4. 11.1.4 Ulcerative Colitis
      5. 11.1.5 Ankylosing Spondylitis
      6. 11.1.6 Others
      11.2 By Distribution Channel Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.2.1 Hospital Pharmacies
      2. 11.2.2 Specialty Clinics
      11.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.3.1 Brazil
      2. 11.3.2 Mexico
      3. 11.3.3 Argentina
      4. 11.3.4 Peru
      5. 11.3.5 Colombia
      6. 11.3.6 Rest of Latin America
      11.4 Latin America Global Adalimumab Drugs Market – Opportunity Analysis Index, By Indication, By Distribution Channel, and Country, 2024 - 2031
      11.5 Regional Trends Analysis
      11.6 Latin America Global Adalimumab Drugs Market Research Report - Company Profiles
      1. 11.6.1 Company 1 (Brazil)
      2. 11.6.2 Company 2 (Mexico)
      3. 11.6.3 Company 3 (Mexico)
    12. Middle East & Africa Global Adalimumab Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 12.1 By Indication Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.1.1 Rheumatoid Arthritis
      2. 12.1.2 Psoriasis
      3. 12.1.3 Crohn's Disease
      4. 12.1.4 Ulcerative Colitis
      5. 12.1.5 Ankylosing Spondylitis
      6. 12.1.6 Others
      12.2 By Distribution Channel Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.2.1 Hospital Pharmacies
      2. 12.2.2 Specialty Clinics
      12.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.3.1 Saudi Arabia
      2. 12.3.2 UAE
      3. 12.3.3 South Africa
      4. 12.3.4 Egypt
      5. 12.3.5 Israel
      6. 12.3.6 Rest of Middle East and Africa
      12.4 Middle East & Africa Global Adalimumab Drugs Market – Opportunity Analysis Index, By Indication, By Distribution Channel, and Country, 2024 - 2031
      12.5 Regional Trends Analysis
      12.6 Middle East & Africa Global Adalimumab Drugs Market Research Report - Company Profiles
      1. 12.6.1 Company 1 (Saudi Arabia)
      2. 12.6.2 Company 2 (UAE)
      3. 12.6.3 Company 3 (UAE)
    13. Competition Landscape
    1. 13.1 Strategic Dashboard of Top Market Players
      13.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 13.2.1 AbbVie Inc.
      2. 13.2.2 Pfizer Inc.
      3. 13.2.3 Amgen Inc.
      4. 13.2.4 Boehringer Ingelheim GmbH
      5. 13.2.5 Sandoz International GmbH (a Novartis division)
    14. Data Collection Method and Research Approach
    15. Principal Presumptions and Acronyms



    2.